{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-183411","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.996675+00:00","generated_at":"2026-05-15T02:43:33.989926+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ZBH Q1 net sales $2.09B (+9.3% reported); adj EPS $2.09 (+15.5%); raises FY adj EPS guidance to $8.40-$8.55","bullets":["Q1 net sales $2.087B, +9.3% reported, +6.8% constant currency, +2.9% organic constant currency.","GAAP diluted EPS $1.22 (+34.1%); adjusted diluted EPS $2.09 (+15.5%).","Operating cash flow $359.4M, free cash flow $245.9M in Q1.","Repurchased $250M of shares during the first quarter.","FY2026 adj EPS guidance raised to $8.40-$8.55 (from $8.30-$8.45); organic CC revenue guidance unchanged at 1-3%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-183411","json":"https://secwatch.observer/filing/0001193125-26-183411.json","markdown":"https://secwatch.observer/filing/0001193125-26-183411.md","text":"https://secwatch.observer/filing/0001193125-26-183411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183411/0001193125-26-183411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183411/zbh-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:43:33.989926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66c328cc5bacf934b44ceada1e037cd24723ad37","claim":"ZIMMER BIOMET HOLDINGS, INC. reported the fiscal year ending December 31, 2026 results: EPS $8.40 - $8.55. Guidance raised.","evidence_excerpt":"The Company is updating its full-year 2026 financial guidance as follows:","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183411/0001193125-26-183411-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ending December 31, 2026"},{"label":"EPS","value":"$8.40 - $8.55"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"bf17dbc8685784e0c83fdd46dbad9e5615437d8b","claim":"ZIMMER BIOMET HOLDINGS, INC. reported the quarter ended March 31, 2026 results: revenue $2.087 billion, net income $238.1 million, EPS $1.22.","evidence_excerpt":"The Company reported first quarter net sales of $2.087 billion, an increase of 9.3% over the prior year period, an increase of 6.8% on a constant currency 1 basis and an increase of 2.9% on an organic constant currency 1 basis.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526183411/0001193125-26-183411-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$2.087 billion"},{"label":"Net income","value":"$238.1 million"},{"label":"EPS","value":"$1.22"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}